Cargando…
15-Epi-LXA(4) and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture
Resolution of inflammation is poorly understood in Achilles tendon disorders. Herein, we investigated the bioactive lipid mediator profiles of tendon-derived stromal cells isolated from patients with Achilles tendinopathy (AT) or Achilles rupture (AR) under baseline and IL-1β–stimulated conditions....
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Federation of American Societies for Experimental Biology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593888/ https://www.ncbi.nlm.nih.gov/pubmed/30916999 http://dx.doi.org/10.1096/fj.201900196R |
_version_ | 1783430144580386816 |
---|---|
author | Dakin, Stephanie G. Colas, Romain A. Newton, Julia Gwilym, Stephen Jones, Natasha Reid, Hamish A. B. Wood, Simon Appleton, Louise Wheway, Kim Watkins, Bridget Dalli, Jesmond Carr, Andrew J. |
author_facet | Dakin, Stephanie G. Colas, Romain A. Newton, Julia Gwilym, Stephen Jones, Natasha Reid, Hamish A. B. Wood, Simon Appleton, Louise Wheway, Kim Watkins, Bridget Dalli, Jesmond Carr, Andrew J. |
author_sort | Dakin, Stephanie G. |
collection | PubMed |
description | Resolution of inflammation is poorly understood in Achilles tendon disorders. Herein, we investigated the bioactive lipid mediator profiles of tendon-derived stromal cells isolated from patients with Achilles tendinopathy (AT) or Achilles rupture (AR) under baseline and IL-1β–stimulated conditions. We also determined whether incubating these cells with 2 of the mediators produced by tendon-derived stromal cells, 15-epi-Lipoxin A(4) (15-epi-LXA(4)) or maresin (MaR)-1, moderated their proinflammatory phenotype. Under baseline conditions, AT cells showed concurrent increased levels of proinflammatory eicosanoids and proresolving mediators compared with AR cells. IL-1β treatment induced profound prostaglandin E(2) release in AR compared with AT cells. Incubation of IL-1β treated AT and AR tendon-derived stromal cells in 15-epi-LXA(4) or MaR1 reduced proinflammatory eicosanoids and potentiated the release of proresolving mediators. These mediators also induced specialized proresolving mediator (SPM) biosynthetic enzymes arachidonate lipoxygenase (ALOX) 12 and ALOX15 and up-regulated the proresolving receptor ALX compared with vehicle-treated cells. Incubation in 15-epi-LXA(4) or MaR1 also moderated the proinflammatory phenotype of AT and AR cells, regulating podoplanin, CD90, signal transducer and activator of transcription (STAT)-1, IL-6, IFN regulatory factor (IRF) 5, and TLR4 and suppressed c-Jun N-terminal kinase 1/2/3, Lyn, STAT-3, and STAT-6 phosphokinase signaling. In summary, we identify proresolving mediators that are active in AT and AR and propose SPMs, including 15-epi-LXA(4) or MaR1, as a potential strategy to counterregulate inflammatory processes in these cells.—Dakin, S. G., Colas, R. A., Newton, J., Gwilym, S., Jones, N., Reid, H. A. B., Wood, S., Appleton, L., Wheway, K., Watkins, B., Dalli, J., Carr, A. J. 15-Epi-LXA(4) and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture. |
format | Online Article Text |
id | pubmed-6593888 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Federation of American Societies for Experimental Biology |
record_format | MEDLINE/PubMed |
spelling | pubmed-65938882019-07-01 15-Epi-LXA(4) and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture Dakin, Stephanie G. Colas, Romain A. Newton, Julia Gwilym, Stephen Jones, Natasha Reid, Hamish A. B. Wood, Simon Appleton, Louise Wheway, Kim Watkins, Bridget Dalli, Jesmond Carr, Andrew J. FASEB J Research Resolution of inflammation is poorly understood in Achilles tendon disorders. Herein, we investigated the bioactive lipid mediator profiles of tendon-derived stromal cells isolated from patients with Achilles tendinopathy (AT) or Achilles rupture (AR) under baseline and IL-1β–stimulated conditions. We also determined whether incubating these cells with 2 of the mediators produced by tendon-derived stromal cells, 15-epi-Lipoxin A(4) (15-epi-LXA(4)) or maresin (MaR)-1, moderated their proinflammatory phenotype. Under baseline conditions, AT cells showed concurrent increased levels of proinflammatory eicosanoids and proresolving mediators compared with AR cells. IL-1β treatment induced profound prostaglandin E(2) release in AR compared with AT cells. Incubation of IL-1β treated AT and AR tendon-derived stromal cells in 15-epi-LXA(4) or MaR1 reduced proinflammatory eicosanoids and potentiated the release of proresolving mediators. These mediators also induced specialized proresolving mediator (SPM) biosynthetic enzymes arachidonate lipoxygenase (ALOX) 12 and ALOX15 and up-regulated the proresolving receptor ALX compared with vehicle-treated cells. Incubation in 15-epi-LXA(4) or MaR1 also moderated the proinflammatory phenotype of AT and AR cells, regulating podoplanin, CD90, signal transducer and activator of transcription (STAT)-1, IL-6, IFN regulatory factor (IRF) 5, and TLR4 and suppressed c-Jun N-terminal kinase 1/2/3, Lyn, STAT-3, and STAT-6 phosphokinase signaling. In summary, we identify proresolving mediators that are active in AT and AR and propose SPMs, including 15-epi-LXA(4) or MaR1, as a potential strategy to counterregulate inflammatory processes in these cells.—Dakin, S. G., Colas, R. A., Newton, J., Gwilym, S., Jones, N., Reid, H. A. B., Wood, S., Appleton, L., Wheway, K., Watkins, B., Dalli, J., Carr, A. J. 15-Epi-LXA(4) and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture. Federation of American Societies for Experimental Biology 2019-07 2019-03-27 /pmc/articles/PMC6593888/ /pubmed/30916999 http://dx.doi.org/10.1096/fj.201900196R Text en © The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Dakin, Stephanie G. Colas, Romain A. Newton, Julia Gwilym, Stephen Jones, Natasha Reid, Hamish A. B. Wood, Simon Appleton, Louise Wheway, Kim Watkins, Bridget Dalli, Jesmond Carr, Andrew J. 15-Epi-LXA(4) and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture |
title | 15-Epi-LXA(4) and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture |
title_full | 15-Epi-LXA(4) and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture |
title_fullStr | 15-Epi-LXA(4) and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture |
title_full_unstemmed | 15-Epi-LXA(4) and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture |
title_short | 15-Epi-LXA(4) and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture |
title_sort | 15-epi-lxa(4) and mar1 counter inflammation in stromal cells from patients with achilles tendinopathy and rupture |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593888/ https://www.ncbi.nlm.nih.gov/pubmed/30916999 http://dx.doi.org/10.1096/fj.201900196R |
work_keys_str_mv | AT dakinstephanieg 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture AT colasromaina 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture AT newtonjulia 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture AT gwilymstephen 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture AT jonesnatasha 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture AT reidhamishab 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture AT woodsimon 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture AT appletonlouise 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture AT whewaykim 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture AT watkinsbridget 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture AT dallijesmond 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture AT carrandrewj 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture |